GLOBAL ATOPIC DERMATITIS DRUGS MARKET FORECAST 2019-2027

  • You are here:
  • Home
  • Reports
  • GLOBAL ATOPIC DERMATITIS DRUGS MARKET FORECAST 2019-2027

GLOBAL ATOPIC DERMATITIS DRUGS MARKET FORECAST 2019-2027

Atopic Dermatitis is a chronic eczematous skin disease, in which the skin becomes extremely itchy and inflamed, causing vesicle formation (minute blisters), cracking, redness, swelling, weeping, crusting, and scaling. Global Atopic Dermatitis Drugs market is anticipated to grow with a CAGR of 4.77% over the forecast period. The base year considered for the study is 2018 and the forecast period is 2019-2027.

GLOBAL ATOPIC DERMATITIS DRUGS MARKET FORECAST 2019-2027

Global Atopic Dermatitis Drugs Market by Route of Administration (Roa) (Topical, Oral, Injectable) by Drug Class (Topical Antibiotics, Topical Antihistamines, Topical Corticosteroids, Topical Moisturizers/emollients, Topical Calcineurin Inhibitors, Immunomodulators, Off-label Therapies, Systemic Agents, Pde-4 Inhibitor, Interleukin Inhibitor) by Geography

Request free sample

Atopic Dermatitis is a chronic eczematous skin disease, in which the skin becomes extremely itchy and inflamed, causing vesicle formation (minute blisters), cracking, redness, swelling, weeping, crusting, and scaling. Global Atopic Dermatitis Drugs market is anticipated to grow with a CAGR of 4.77% over the forecast period. The base year considered for the study is 2018 and the forecast period is 2019-2027.

The Global Atopic Dermatitis Drugs market is primarily driven by the following factors:

  • Growing prevalence of food allergies exacerbating atopic dermatitis
  • Growing focus on systematic therapies
  • Increasing use of pharmacological products in developing countries

To know more about this report, request a free sample copy

The important driver increasing growth in the global atopic dermatitis drugs market is the growing prevalence of food allergies that are exacerbating atopic dermatitis. According to a research, food allergy and severe atopic dermatitis coexist in approximately one-third of all children with atopic dermatitis. These food allergies are mainly caused by chicken eggs, cow’s milk, peanuts, wheat, nuts, soy, and fish. Also, atopic dermatitis once appeared in childhood can exacerbate with time.

Poor patient adherence due to inadequate information on drug usage is the major factor hindering the atopic dermatitis drugs market. After some observance, it could be said that even in specialist centres, the patient outcomes are not positive owing to non-administered treatment. This is primarily due to the inadequate time spent on patients for educating them about atopic dermatitis and medications by the physicians. As a result, the extent of side effects and the threat of toxicity associated with atopic dermatitis drugs increases due to the unawareness of the proper drug usage.

The Global Atopic dermatitis drugs market segments include Route of Administration (ROA) and Drug Class.

 

Route of Administration is segmented into:

  • Topical
  • Oral
  • Injectable

Drug Classes are segmented into:

  • Topical Antibiotics
  • Topical Antihistamines
  • Topical Corticosteroids
  • Topical Moisturizers/Emollients
  • Topical Calcineurin Inhibitors
  • Immunomodulators
  • Off-Label Therapies
  • Systemic Agents
  • Pde-4 Inhibitor
  • Interleukin Inhibitor

This report covers the present market conditions and the growth prospects of the global atopic dermatitis drugs market for 2019-2027 and considered the revenue generated through the sales of atopic dermatitis drugs for the route of administration as well as drug class to calculate the market size by considering 2018 as the base year.

Geographically, the Atopic Dermatitis Drugs market has been segmented on the basis of four major regions, which include:

The Atopic Dermatitis Drugs market in North America is expected to hold the largest share by 2027. The growth in the North America region is mainly driven by growing incidence of allergic conditions among the population which has increased the growth in atopic dermatitis drugs market. The government in North American countries such as the USA are also contributing towards the growth of the North America atopic dermatitis drugs market. The government has stringent regulations and norms for these drugs but, at the same time, is putting efforts to decrease the duration of clinical trials for the same. The United States holds the largest revenue share in the global atopic dermatitis drugs market. The accessibility to therapies by reimbursement programs is further expected to result in a high turnout of patients opting for treatment, thus propelling the growth of the market in the US.

The atopic dermatitis drugs market is segmented based on its Route of Administration; which are sub-divided into oral, topical and injectable. Route of Administration (ROA) determines the time taken for a drug to undergo its mechanism of action and show its efficacy. The antibiotics given for oral treatment are also used for intravenous treatments. These antibiotics are effective in managing atopic dermatitis, especially when the skin shows signs of bacterial infection such as weeping, pustules, crusting, or painful swelling (cellulitis). Topical ROA is the most effective treatment with the least side effects. These drugs are applied directly to the skin like ointments or creams. Injectable ROA is the least used out of the three and has a very less market share.

The major market players in the global atopic dermatitis drugs market are:

  • Leo Pharma
  • Meda Pharmaceuticals (Mylan)
  • Valent Pharmaceutical Inc
  • Bayer Ag
  • Encore Dermatology

Company Profiles covers analysis of important players.

LEO Pharma AS (LEO Pharma) (LEO), a company owned by LEO Foundation, is an independent, research-based pharmaceutical company. The company develops, manufactures and markets pharmaceutical drugs for dermatologic and thrombotic patients. The company operates in Europe, the Middle East, Africa, Asia Pacific, and the Americas. LEO Pharma is headquartered in Ballerup, Denmark. Another company, Valeant Pharmaceuticals International Inc. (Valeant or ‘the company’) is a multinational specialty pharmaceutical company engaged in the development, manufacture, and marketing of pharmaceutical products primarily in the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. The company markets its products in the US, Canada, Europe, the Middle East, Latin America, Asia Pacific, and Africa. It is headquartered in Quebec, Canada.

Key Findings of the Global Atopic Dermatitis Drugs market:

  • North America generated the largest chunk of global revenue
  • Topical route of administration holds the majority of the overall market share
  • Interleukin inhibitor market is anticipated to generate the highest revenue
  1. RESEARCH SCOPE
    • STUDY GOALS
    • SCOPE OF THE MARKET STUDY
    • WHO WILL FIND THIS REPORT USEFUL?
    • STUDY AND FORECASTING YEARS
  2. RESEARCH METHODOLOGY
    • SOURCES OF DATA
      • SECONDARY DATA
      • PRIMARY DATA
    • TOP-DOWN APPROACH
    • BOTTOM-UP APPROACH
    • DATA TRIANGULATION
  3. EXECUTIVE SUMMARY
    • MARKET SUMMARY
    • KEY FINDINGS
      • NORTH AMERICA GENERATED THE LARGEST CHUNK OF THE GLOBAL REVENUE
      • TOPICAL ROUTE OF ADMINISTRATION HOLDS MAJORITY OF THE OVERALL MARKET SHARE
      • INTERLEUKIN INHIBITOR MARKET IS ANTICIPATED TO GENERATE HIGHEST REVENUE
  1. MARKET DETERMINANTS
    • MARKET DRIVERS
      • GROWING PREVALENCE OF FOOD ALLERGIES EXACERBATING ATOPIC DERMATITIS
      • GROWING FOCUS ON SYSTEMATIC THERAPIES
      • INCREASING USE OF PHARMACOLOGICAL PRODUCTS IN DEVELOPING COUNTRIES
    • MARKET RESTRAINTS
      • STRINGENT REGULATIONS FOR PRODUCT APPROVAL
      • GENERIC COMPETITION
    • MARKET OPPORTUNITIES
      • INCREASING M&A LEADING TO MARKET CONSOLIDATION
      • LAUNCH OF FIRST BIOLOGIC FOR ATOPIC DERMATITIS
      • GROWING FOCUS ON NOVEL DRUGS
    • MARKET CHALLENGES
      • BLACK BOX WARNING FOR ELIDEL AND PROTOPIC
      • HIGHLY GENERICIZED MARKET
      • POOR PATIENT ADHERENCE DUE TO INADEQUATE INFORMATION ON DRUG USAGE
  1. MARKET SEGMENTATION
    • MARKET BY ROUTE OF ADMINISTRATION (ROA) 2019-2027
      • TOPICAL
      • ORAL
      • INJECTIBLES
    • MARKET BY DRUG CLASS 2019-2027
      • TOPICAL ANTIBIOTICS
      • TOPICAL ANTIHISTAMINES
      • TOPICAL CORTICOSTEROIDS
      • TOPICAL MOISTURIZERS/EMOLLIENTS
      • TOPICAL CALCINEURIN INHIBITORS
      • IMMUNOMODULATORS
      • OFF-LABEL THERAPIES
      • SYSTEMIC AGENTS
      • PDE4 INHIBITOR
      • INTERLEUKIN INHIBITOR
  1. KEY ANALYTICS
    • PORTER’S FIVE FORCE ANALYSIS
      • THREAT OF NEW ENTRANTS
      • THREAT OF SUBSTITUTE
      • BARGAINING POWER OF SUPPLIERS
      • BARGAINING POWER OF BUYERS
      • THREAT OF COMPETITIVE RIVALRY
    • OPPORTUNITY MATRIX
    • PIPELINE ANALYSIS
    • LEGAL, POLICY AND REGULATORY ISSUES
  2. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • GERMANY
      • FRANCE
      • THE UNITED KINGDOM
      • RUSSIA
      • ITALY
      • REST OF EUROPE
    • ASIA-PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • AUSTRALIA AND NEW ZEALAND
      • SOUTH KOREA
      • REST OF ASIA PACIFIC
    • REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST AND AFRICA
  1. COMPANY PROFILES
    • ALLERGAN PLC
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • AQUA PHARMACEUTICALS (AN ALMIRALL COMPANY)
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
    • ASTELLAS PHARMA INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • BAYER AG
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • BIOFRONTERA AG
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
    • BRISTOL-MYERS SQUIBB
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
    • STIEFEL LABORATORIES, INC
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
    • ENCORE DERMATOLOGY
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • GALDERMA SA
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • LEO PHARMA
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • MEDA PHARMACEUTICALS (MYLAN N.V.)
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • NOVARTIS AG
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • PFIZER
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • REGENERON PHARMACEUTICALS
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • SANOFI SA
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS
      • STRATEGIC INITIATIVES
    • VALENT PHARMACEUTICAL INC.
      • COMPANY OVERVIEW
      • PRODUCT PORTFOLIO
      • SWOT ANALYSIS

LIST OF TABLES

TABLE  1      GLOBAL ATOPIC DERMATITIS DRUGS MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  2      RECENT MERGERS AND ACQUISITIONS IN ATOPIC DERMATITIS DRUGS MARKET

TABLE  3      GLOBAL ATOPIC DERMATITIS DRUGS MARKET BY ROA 2019-2027 ($ MILLION)

TABLE  4      GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ROA BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  5      GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN ORAL  ROA BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  6      GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN INJECTIBLES ROA BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  7      GLOBAL ATOPIC DERMATITIS DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)

TABLE  8      GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIBIOTICS BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  9      GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIHISTAMINES BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  10    GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CORTICOSTEROIDS BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  11    GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL MOISTURIZERS/EMOLLIENTS BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  12    GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CALCINEURIN INHIBITORS BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  13    GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN IMMUNOMODULATORS BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  14    GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN OFF-LABEL THERAPIES BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  15    GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN SYSTEMIC AGENTS BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  16    GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN PDE4 INHIBITOR BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  17    GLOBAL ATOPIC DERMATITIS DRUGS MARKET IN INTERLEUKIN INHIBITOR BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  18    PIPELINE PORTFOLIO OF DIABETES DRUGS MARKET

TABLE  19    REGULATORY FRAMEWORK IN ATOPIC DERMATITIS MARKET

TABLE  20    GLOBAL ATOPIC DERMATITIS DRUGS MARKET BY GEOGRAPHY 2019-2027 ($ MILLION)

TABLE  21    NORTH AMERICA ATOPIC DERMATITIS DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

TABLE  22    EUROPE ATOPIC DERMATITIS DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

TABLE  23    ASIA-PACIFIC ATOPIC DERMATITIS DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

TABLE  24    REST OF THE WORLD ATOPIC DERMATITIS DRUGS MARKET 2019-2027 (IN $ MILLION)

LIST OF FIGURES

FIGURE  1    GLOBAL ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  2    THE UNITED STATES ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  3    CANADA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  4    GERMANY ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  5    FRANCE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  6    THE UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  7    RUSSIA ATOPIC DERMATITIS DRUGS MARKET, 2019-2027 ($ MILLION)

FIGURE  8    ITALY ATOPIC DERMATITIS DRUGS MARKET, 2019-2027 ($ MILLION)

FIGURE  9    REST OF EUROPE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  10  INDIA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  11  CHINA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  12  JAPAN ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  13  AUSTRALIA AND NEW ZEALAND ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  14  SOUTH KOREA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  15  REST OF ASIA PACIFIC ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)

FIGURE  16  LATIN AMERICA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 (IN $ MILLION)

FIGURE  17  MIDDLE EAST AND AFRICA ATOPIC DERMATITIS DRUGS MARKET 2019-2027 (IN $ MILLION)

  1. MARKET SEGMENTATION
    • MARKET BY ROUTE OF ADMINISTRATION (ROA) 2019-2027
      • TOPICAL
      • ORAL
      • INJECTIBLES
    • MARKET BY DRUG CLASS 2019-2027
      • TOPICAL ANTIBIOTICS
      • TOPICAL ANTIHISTAMINES
      • TOPICAL CORTICOSTEROIDS
      • TOPICAL MOISTURIZERS/EMOLLIENTS
      • TOPICAL CALCINEURIN INHIBITORS
      • IMMUNOMODULATORS
      • OFF-LABEL THERAPIES
      • SYSTEMIC AGENTS
      • PDE4 INHIBITOR
      • INTERLEUKIN INHIBITOR
  1. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    • EUROPE
      • GERMANY
      • FRANCE
      • THE UNITED KINGDOM
      • RUSSIA
      • ITALY
      • REST OF EUROPE
    • ASIA-PACIFIC
      • INDIA
      • CHINA
      • JAPAN
      • AUSTRALIA AND NEW ZEALAND
      • SOUTH KOREA
      • REST OF ASIA PACIFIC
    • REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST AND AFRICA

To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now